Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024)

Historic Current Deferred Revenue for BioLineRx (BLRX) over the last 2 years, with Q3 2024 value amounting to $2.3 million.

  • BioLineRx's Current Deferred Revenue changed N/A to $2.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $13.0 million for FY2023, which is N/A changed from last year.
  • Per BioLineRx's latest filing, its Current Deferred Revenue stood at $2.3 million for Q3 2024.
  • In the past 5 years, BioLineRx's Current Deferred Revenue ranged from a high of $13.0 million in Q4 2023 and a low of $2.3 million during Q3 2024